NoahMHahnMD

Summary

• I am a professor of oncology and urology at the Johns Hopkins University School of Medicine. I serve as the director of the medical oncology bladder cancer program and the deputy director of the Johns Hopkins Greenberg Bladder Cancer Institute. Throughout my career, I have led numerous bladder cancer novel therapeutic clinical trials and translational investigations. I maintain an active clinical practice and see patients with urothelial cancers of all locations and stages including non-muscle invasive bladder cancer. My clinical and translational research interests focus on improving outcomes for patients with urothelial cancers through: 1) The development of novel epigenetic, targeted, and immunomodulatory approaches to treat and prevent urothelial cancer; 2) The credentialing of the naturally-occurring, immunocompetent canine-human tumor model as a relevant comparative oncology model optimal for the pre-clinical study of candidate human urothelial cancer biomarkers and therapeutics; and 3) The identification and validation of predictive biomarkers relevant to urothelial cancers. In addition to my efforts at Johns Hopkins, I also serve as the bladder cancer chairman of the Eastern Cooperative Oncology Group (ECOG), am the immediate past co-chair of the Hoosier Cancer Research Network genitourinary oncology clinical trials working group, participate on the NCI Bladder Cancer Task Force, and serve on the scientific advisory board of the Bladder Cancer Advocacy Network.